Kotak Mahindra Capital Company Limited
Credit Suisse Securities (India) Private Limited
Jefferies India Private Limited
JM Financial Consultants Private Limited
Global Health Limited is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India. The company has key specialities in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology.
Global Health Limited have a network of four hospitals currently in operation (Gurugram, Indore, Ranchi and Lucknow) under the “Medanta” brand. The company established “The Medanta Institutional Tissue Repository” in 2017 to promote biomarker and other tissue-based research.
In Fiscals 2020, 2021 and 2022 and the three months ended June 30, 2021 and 2022, the company generated income from healthcare services of Rs. 14,805.71 million, Rs. 14,178.41 million, Rs. 21,003.95 million, Rs. 4,732.10 million and Rs. 5,960.89 226 million, respectively, and had EBITDA of Rs. 2,304.54 million, Rs. 2,228.52 million, Rs. 4,897.57 million, Rs. 1,057.69 million and Rs. 1,416.46 million, respectively.
As of June 30, 2022, the company provide healthcare services in over 30 medical specialities and engage over 1,300 doctors led by experienced department heads, spanning an area of 4.7 million sq. ft., the operational hospitals have 2,467 installed beds.
Global Health Limited’s hospital at Gurugram was ranked as the best private hospital in India for three consecutive years in 2020, 2021 and 2022, and was the only Indian private hospital to be featured in the list of top 200 global hospitals in 2021 and was featured in the list of top 250 global hospitals in 2022 by Newsweek
For year/ period ended ( in Cr.)
|Profit After Tax||196.20||28.81||36.33|
Global Health is operating under the most popular healthcare brand “Medanta” and posted growth over the years in its scale of operations. The issue is attractively priced based on its financial data and well compares with listed peers. Hence, Investors may subscribe to the Issue
Never Miss IPO Investment